CUSABIO Phage Display Service

CUSABIO has been specialized in applying advanced phage display technologies for a wide range of service projects. With years of experience, we can offer high-quality phage display library construction and custom phage display library screening services to meet your various demands precisely. We are confident that our phage display technologies could allow you have new opportunities in immunotherapy, drug discovery, and functional genomics.

Introduction of Phage Display Technology

Phage display is the technology that inserts the DNA sequence of foreign protein or peptide into the appropriate position of phage coat protein structural gene, so that the exogenous gene can be expressed along with the expression of phage coat protein itself. Meanwhile, the foreign protein also can be shown in the surface of phage coat protein following the reassembly of phage. In short, a phage library expressing a wide diversity of peptides or proteins is used to select those binding the desired targets.

Classification of Phage Display Systems

Based on different phages, vectors or libraries, the phage display systems could be divided into various types, details as below.

Based on Different Phages phage service symbol 01 M13, f1, fd
T7, T4, lamda
Different Phages of Phage Display Systems
Different Phages of Phage Display Systems
Based on Different Vectors phage service symbol 02 Viral Vector
Different Vectors of Phage Display Systems
Based on Different Libraries cDNA Library
Antibody Library
Protein Library
Random Peptide Library

What phage display services could CUSABIO offer to you?

CUSABIO could provide phage display technologies to customers that cover the broad scope of the technologies including key areas of library construction and screening as well as antibody modification and expression.

1. Phage Display Library Construction

The phage display library technology refers to the clone and expression for variable region genes of all antibodies from a certain animal in a plasmid or phage, then screen clones carrying specific antibody genes via different antigens, thereby, to obtain corresponding specific antibodies or peptides.

CUSABIO is committed to offering quality services of antibody library construction as well as peptide library construction to customers.

phage display library construction

CUSABIO Service Process of Phage Display Library Construction

No. Process Service Items Service Cycle
1 Separation of lymphocytes Obtain lymphocytes from peripheral blood, spleen or bone marrow. 1 week
2 RNA isolation and cDNA synthesis RNA extraction, then reverse transcription into cDNA.
3 Construction of recombinant plasmid With cDNA as the template, the antibody gene will be extended with degenerate primer, then inserted into the phage vector. 4 weeks
4 Electro transformation library construction Prepare TG1 infected cells, then transform E. coli by well-constructed recombinant plasmid. 2 weeks
5 Capacity and diversity detection for antibody library Detect antibody library capacity via colony counting, as well as detect antibody library diversity via sequencing.
6 Phage display antibody library preparation To package the antibody library via infecting M13K07 phage. 1 week
7 Phage display antibody library titer detection Infect phage via TG1, then detect antibody library titer via colony counting.
8 Delivery Shipment with ice bags. Depends on express

2. Phage Display Library Screening

CUSABIO is mainly engaged in offering quality and personalized services of antibody library screening as well as peptide library screening to meet customers' various demands.

Phage display library screening

2.1 Antibody Library Screening

CUSABIO can construct antibody libraries as well as screen desired monoclonal antibodies with high specificity and affinity from a wide range of species, such as human, alpaca, mouse, rabbit, chicken, dog, bovine, and so on. Compared with the traditional hybridoma method, antibody phage display library has distinct advantages on selecting novel monoclonal antibodies and even the fully humanized antibody. Furthermore, the antibodies from phage library have following advantages.

  • Short production cycle, because recombinant antitbodies are generated in vitro, which needn’t a long process for animals immunization.
  • Direct screening of human antibodies.
  • Screening antibodies that recognize toxicity or autoantigens.
  • Obtaining antibody genes for further direct modification.

2.2 Peptide Library Screening

As we known, peptides are biological molecules, consisting of short sequences of amino acids, so peptides are easy to be synthesized, show low toxicity and high efficiency. Most importantly, if targeting receptors or molecules that are specially expressed on cancer cells would significantly enhance cancer therapeutic effect and reduce cancer-related mortality as well. Thus phage display technology on screening target peptides for developing cancer drugs absolutely can offer new opportunities for the treatment of many tumor diseases. We are confident the peptide library screening service from CUSABIO can provide more possibilities for your research.

CUSABIO Service Process of Phage Display Library Screening

No. Process Service Items Service Cycle
1 Quality control of antigen Antigen purity detection by SDS-PGAE. 1 week
2 Antibody library screening To obtain the positive clones that recognize antigen through 3-4 rounds of screening. 2 weeks
3 Antibody sequencing Sequencing for positive clones. 1 week
4 Quality control of antibody To express target antibodies in E. coli, then quality control via ELISA. 1 week
5 Delivery Shipment with ice bags. Depends on express

3. Antibody Humanization & Affinity Maturation

Humanized antibodies are antibodies from non-human species whose protein sequences have been modified to increase their similarity to antibody variants produced naturally in human beings.

As for affinity maturation, which is the process to increase their affinity for a particular antigen via their B cells during the course of an immune response. With repeated processes of somatic hypermutation for B-cell receptors and subsequent clonal selection to the same antigen, a host will produce antibodies of successively greater affinities.

Antibody humanization has played a fundamental role in the remarkable progress of antibodies as therapeutic reagents. As we known, since the advent of hybridoma technology, most monoclonal antibodies derive from rodent, such as mouse, rat, rabbit, hamster, etc. But most rodent antibodies have been shown a limited use as therapeutic agents because of a short serum half-life as well as they can not trigger human effector functions. Furthermore, most rodent monoclonal antibodies could be recognized as foreign proteins by the patients’ immune systems, then resulting in a human anti-mouse antibody (HAMA) response. On the other hand, in some cases, the affinity of a certain antibody deriving from phage library may not be high enough for used as therapeutic agents, then affinity maturation is urgently required to preserve the epitope specificity and functional activity of the antibody as well as boost potency to the desired level. Thus antibody humanization & affinity muturation absolutely double strong alliance for the antibody therapeutic applications.

CUSABIO Service Process of Antibody Humanization

No. Process Service Items Service Cycle
1 Antibody sequencing & analyzing
  1. Antibody sequencing report;
  2. Antibody sequence analysis report;
  3. 1-3 antibodies with best affinity;
12-16 weeks
2 Mutation library construction & screening
3 Antibody production & validation

CUSABIO Service Process of Affinity Maturation

No. Process Service Items Service Cycle
1 Antibody sequencing & analyzing
  1. Antibody sequencing report;
  2. Antibody sequence analysis report;
  3. 1-3 antibodies with best affinity;
18-22 weeks
2 Alanine scanning
3 Mutation library construction & screening
4 Antibody production & validation


You can also contact us via [email protected] directly or online message.

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2024 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1